Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 310 pages

Showing 251 - 300


issues in oncology
prostate cancer
issues in oncology

Researchers Discover Genetic Variant That Can Predict Aggressive Prostate Cancer at Diagnosis

Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker adjacent to the KLK3 gene that can predict which prostate cancer patients with a Gleason score of 7 will have a more aggressive form of cancer. The findings by He et al, published in Clinical Cancer...

prostate cancer

ESMO 2014: Abiraterone Plus Prednisone Significantly Improves Overall Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

A final analysis of the phase III COU-AA-302 trial showed that abiraterone acetate (Zytiga) plus prednisone significantly prolonged overall survival compared to an active control of placebo plus prednisone in men with chemotherapy-naive metastatic castration-resistant prostate cancer. The study,...

prostate cancer

ASTRO: Long-Term Androgen-Deprivation Therapy Plus High-Dose Radiation Therapy Improves Biochemical Control and Survival Rates in Prostate Cancer

Prostate cancer patients who receive high-dose radiation therapy followed by a longer period of androgen-deprivation therapy have higher 5-year biochemical disease–free survival and overall survival rates compared to patients who receive high-dose radiation therapy and a shorter duration of...

prostate cancer

ASTRO: Shorter Course of Androgen-Deprivation Therapy Yields Improved Quality of Life for High-Risk Prostate Cancer Patients

Patients with high-risk prostate cancer who received radiation therapy and an 18-month course of androgen-deprivation therapy recovered a normal testosterone level in a shorter amount of time compared to those who received a 36-month course of androgen-deprivation therapy. The shorter course of...

prostate cancer

FDA Approves New Indication for Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

The U.S. Food and Drug Administration (FDA) has approved a new indication for the use of enzalutamide (Xtandi) capsules to treat patients with metastatic castration-resistant prostate cancer. The new indication is for men with metastatic castration-resistant prostate cancer who have not received...

prostate cancer

ASCO and Cancer Care Ontario Release Clinical Practice Guideline for Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer

The ASCO Clinical Practice Guidelines Committee and the Cancer Care Ontario (CCO) program in evidence-based care have released a clinical practice guideline on systemic therapy in men with metastatic castration-resistant prostate cancer. The guideline is reported by Basch et al in the Journal of...

prostate cancer
issues in oncology

RNA Sequencing Could Help Doctors Tailor Unique Prostate Cancer Treatment Programs

Sequencing RNA, not just DNA, could help doctors predict how prostate cancer tumors will respond to treatment, according to research published in the journal Genome Biology. Because a tumor’s RNA shows the real-time changes a treatment is causing, the authors believe that this could be a...

prostate cancer

Study Finds Widespread Adoption of Robot-Assisted Prostatectomy in United States

A new study reveals that the United States has experienced widespread adoption of robot-assisted prostatectomy to treat prostate cancer in recent years. The findings, reported by Chang et al in BJU International, also showed that although such surgeries are more expensive than traditional...

prostate cancer
issues in oncology

Swedish Study Reports Increasing Rates of Severe Infection Requiring Hospitalization After Prostate Biopsy

Transrectal ultrasound guided biopsy is the standard for detecting prostate cancer, but international reports have suggested that the risks associated with the procedure are increasing. In a new nationwide population-based study reported in The Journal of Urology, Swedish researchers found that 6%...

issues in oncology
prostate cancer

Prostate Cancer Prevention Trial Identifies Men Most Likely to Undergo Challenging Study Procedures

Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all steps of the clinical trial are most likely to undergo a biopsy, according to a study by Gritz et al published in Cancer Epidemiology, Biomarkers & Prevention. The Prostate Cancer Prevention Trial, ...

prostate cancer

College of American Pathologists Publishes Recommendations for Prostate Cancer Active Surveillance

Prostate cancer is the second leading cause of cancer death in men in the United States. Active surveillance offers low-risk prostate cancer patients a means to avoid the potentially harmful side effects from treatment. In a recent article in the Archives of Pathology & Laboratory Medicine, a...

prostate cancer

Robot-Assisted Surgery for Localized Prostate Cancer Controls Disease for 10 Years

Robot-assisted surgery to remove cancerous prostate glands is effective in controlling the disease for 10 years, according to a new study led by researchers at Henry Ford Hospital. The study by Diaz et al, published in European Urology, also suggested that traditional methods of measuring the...

prostate cancer

Variations in Key Gene Predict Prostate Cancer Patients’ Risk for Radiation-Induced Toxicity

Key genetic variants may affect how cancer patients respond to radiation treatments, according to a study recently published in Nature Genetics. The research team, which included researchers at the Icahn School of Medicine at Mount Sinai, found that variations in the TANC1 gene are associated with...

prostate cancer

Development of Orteronel for Prostate Cancer Voluntarily Discontinued by Takeda

Takeda Pharmaceutical Company Limited announced today that it has voluntarily decided to end the development program for orteronel (TAK-700), an investigational oral, nonsteroidal, selective inhibitor of 17,20-lyase, for prostate cancer. The decision follows the results of two phase III...

prostate cancer

ASCO 2014: Men Who Receive Radiation Therapy for Prostate Cancer Have Increased Long-Term Risk of Bladder or Rectal Cancer

Men with prostate cancer generally have an excellent prognosis, but questions remain about the risk of second primary malignancies after initial therapy for localized disease. According to a new study presented at the 2014 ASCO Annual Meeting in Chicago (Abstract 5034), although the overall risk of ...

prostate cancer
issues in oncology

Study Reveals More Than One-Third of Patients With ‘Low-Risk’ Prostate Cancer on Conventional Biopsy Have More Aggressive Tumors on Targeted Biopsy

According to a new study by researchers at the University of California, Los Angeles, selection of men for active surveillance for prostate cancer should be based not on conventional biopsy, but on a new, imaging-guided targeted prostate biopsy. The new biopsy method is now a routine part of the...

prostate cancer

Results of Three Studies Indicate 17-Gene Assay Is a Significant Predictor of Prostate Cancer Aggressiveness at the Time of Diagnosis

According to the results from three studies published in European Urology, the 17-gene Oncotype DX Genomic Prostate Score is a significant predictor of disease aggressiveness at the time of diagnosis before intervention with radiation or surgery. The test provides more precise and individualized...

prostate cancer

Delaying Androgen Deprivation Therapy May Be Safe for Men With Prostate Cancer Relapse Detected by PSA Testing

According to a large, population-based observational study of men who had a prostate-specific antigen (PSA)-only based relapse after prostate surgery or radiation therapy, delaying androgen deprivation therapy until the onset of symptoms or appearance of cancer on a scan does not substantially...

prostate cancer

Statin Use Associated With Reduced Risk of Prostate Cancer Recurrence

Men who begin taking statins after prostate cancer surgery are less likely to have a recurrence of their cancer, according to a retrospective analysis led by researchers at Duke Medicine. The study by Allott et al was published in BJU International. “Our findings suggest that beginning...

prostate cancer

Experimental Drug Receives Fast Track Designation as Second-Line Chemotherapy for Metastatic Castration-Resistant Prostate Cancer

OncoGenex Pharmaceuticals, Inc, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of custirsen (OGX-011) when administered in combination with cabazitaxel (Jevtana Kit)/prednisone for the treatment of men with metastatic...

prostate cancer

Study Finds a Quarter of Men Drop Out of Prostate Cancer Monitoring, Casting Doubt on Safety of Active Surveillance

Noncompliance appears to be a major challenge for active surveillance, according to the results of long-term follow-up of patients with prostate cancer presented at the European Association of Urology 29th Annual Congress in Stockholm. Over a quarter of men dropped out of the active surveillance...

prostate cancer

Six Months Hormonal Treatment in Addition to Radiotherapy Improves Survival for Men With Localized Prostate Cancer

Men with localized prostate cancer that is at risk of growing and spreading have a lower risk of disease progression and recurrence if they are treated with radiotherapy combined with androgen-deprivation therapy, according to new research. The findings, which were presented at the 33rd Conference...

prostate cancer
issues in oncology

New Test Developed to Detect Men at High Risk of Prostate Cancer Recurrence

A new genetic signature to identify prostate cancer patients who are at high risk of their cancer recurring after surgery or radiotherapy has been developed by researchers in Canada, according to a study presented at the 33rd Conference of the European Society for Radiotherapy and Oncology in...

prostate cancer

Dose-Escalated Hypofractionated IMRT for Localized Prostate Cancer Has Similar Side Effects Compared to Conventional IMRT

Dose-escalated intensity-modulated radiotherapy with use of a moderate hypofractionation regimen (72 Gy in 2.4-Gy fractions) can safely treat patients with localized prostate cancer with limited grade 2 or 3 late toxicity, according to a study by Hoffman et al published in the International Journal ...

issues in oncology
prostate cancer

BPA Exposure May Be Linked to Prostate Cancer, Study Shows

A new study suggests that levels of bisphenola A (BPA) in men’s urine may be a marker of prostate cancer and that low levels of BPA exposure can cause cellular changes in both nonmalignant and malignant prostate cells. The research, published in PLOS ONE, provides the first evidence that...

solid tumors
prostate cancer

Robotic-Assisted Prostate Surgery May Offer Better Cancer Control Than Open Radical Prostatectomy

An observational study from UCLA’s Jonsson Comprehensive Cancer Center comparing robotic-assisted surgery to traditional surgery for prostate cancer found that patients who had robotic surgery had fewer instances of cancer cells remaining after surgery and less need of additional cancer...

prostate cancer

Selenium and Vitamin E Supplements May Increase Risk of Prostate Cancer in Some Men

A multicenter study led by Fred Hutchinson Cancer Research Center has found that high-dose supplementation with both the trace element selenium and vitamin E may increase the risk of high-grade prostate cancer. This risk is dependent upon a man’s selenium status prior to taking the...

prostate cancer

Tasquinimod May Improve Survival in Men With Metastatic Prostate Cancer

An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute. The study, published in the journal Clinical Cancer Research, adds...

issues in oncology
prostate cancer

Shortened Telomeres in Blood Leukocytes May Be Associated With Increased Risk of Aggressive Prostate Cancer

Men with short-ended chromosomes in the immune cells in their blood were at increased risk for aggressive prostate cancer compared with men with long-ended chromosomes in blood immune cells, according to results presented at the 12th Annual AACR International Conference on Frontiers in Cancer...

prostate cancer
survivorship

Men With Advanced Prostate Cancer Worry More About Burdening Family and Friends Than Dying, Survey Finds

Men with advanced prostate cancer are now living longer than ever, and it is estimated that one in six U.S. men will be diagnosed with prostate cancer in their lifetime. However, little research has been conducted to understand the psychosocial needs of these men and their caregivers after...

prostate cancer

Telomere Length May Be a Prognostic Marker for Prostate Cancer

Cancer cells are known to have short telomeres, but just how short they are from cancer cell to cancer cell may be a determining factor in a prostate cancer patient's prognosis, according to a study led by scientists at Johns Hopkins. "Doctors are looking for new ways to accurately predict...

prostate cancer
supportive care

Abiraterone Acetate/Prednisone Combination Delays Decline in Quality of Life in Men With Metastatic Prostate Cancer

According to a study published in The Lancet Oncology, abiraterone acetate (Zytiga) taken in conjunction with prednisone significantly delays progression of pain and quality of life deterioration in men with metastatic castration-resistant prostate cancer. The study was led by Ethan Basch, MD,...

prostate cancer

ASTRO: Fewer Weeks of Neoadjuvant Hormone Therapy Reduces Side Effects in Patients With Intermediate-Risk Prostate Cancer

A shorter course of androgen suppression therapy prior to radiation therapy, when compared to an extended course of androgen suppression therapy, yields comparable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the...

prostate cancer

ASTRO: Long-Term Androgen Deprivation in Patients With Intermediate-Risk Prostate Cancer Does Not Improve Overall Survival

A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy. Investigators concluded that there were no additional benefits when compared to short-term...

prostate cancer
issues in oncology

Test Could Identify Which Prostate Cancers Require Treatment

The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow-growing, according to researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center (CUMC). Use of this three-gene...

prostate cancer
issues in oncology

Germline Missense Mutations in BTNL2 Increase Susceptibility to Prostate Cancer

A team of researchers led by Janet Stanford, PhD, of Fred Hutchinson Cancer Research Center has discovered that mutations in the gene BTNL2, which encodes a protein involved in regulating T-cell proliferation and cytokine production—both of which impact immune function—increase the risk ...

prostate cancer

Researchers Identify Key Protein in Treatment-Resistant Prostate Cancer

Prostate cancer is one of the most common forms of cancer in men and the leading cause of cancer deaths in white, African American, and Hispanic men, according to the Centers for Disease Control. However, it remains unclear why, despite treatment, some prostate cancers progress and may become...

prostate cancer

Researchers Identify Key Mechanism Behind Castration-Resistant Prostate Cancer

A team of researchers from UC Davis, UC San Diego, and other institutions has identified a key mechanism behind aggressive prostate cancer. Published online today in Nature, the study shows that two long noncoding RNAs, PRNCR1 and PCGEM1, activate androgen receptors, circumventing...

prostate cancer

Researchers Uncover How a Potent Compound Kills Prostate Cancer Cells

A new study led by researchers at Sanford-Burnham Medical Research Institute reveals how a promising anticancer compound called SMIP004 specifically kills prostate cancer cells by compromising their ability to withstand environmental stress. The study, recently published in Oncotarget, uncovered...

prostate cancer
issues in oncology

Decision Aids Reduce Men's Conflict about PSA Screening, but Don't Change Their Decisions

Men who decide to be screened for prostate cancer and those who forgo PSA screening stick with their decisions after receiving materials explaining the risks and benefits of the test, according to a study published in JAMA Internal Medicine. The study examined both Web-based and printed tools aimed ...

prostate cancer

Use of Androgen Deprivation Therapy for Treatment of Prostate Cancer Associated with Increased Risk of Acute Kidney Injury

In a study that included more than 10,000 men with nonmetastatic prostate cancer, use of androgen deprivation therapy was associated with a significantly increased risk of acute kidney injury, with variations observed with certain types of androgen deprivation therapies, according to a study in the ...

prostate cancer

Nerves Play Key Role in Triggering Prostate Cancer and Promoting Metastases

Researchers at Albert Einstein College of Medicine of Yeshiva University have found that nerves play a critical role in both the development and spread of prostate tumors. Their findings, using both a mouse model and human prostate tissue, may lead to new ways to predict the aggressiveness of...

issues in oncology
prostate cancer

Study Confirms Link Between High Blood Levels of Omega-3 Fatty Acids and Increased Risk of Aggressive Prostate Cancer

A second large, prospective study by scientists at Fred Hutchinson Cancer Research Center has confirmed the link between high blood concentrations of omega-3 fatty acids and an increased risk of prostate cancer. Study Details Published online in the Journal of the National Cancer Institute, the...

issues in oncology
prostate cancer

Soy Protein Supplementation Does Not Reduce Risk of Prostate Cancer Recurrence after Radical Prostatectomy

Among men who had undergone radical prostatectomy, daily consumption of a beverage powder supplement containing soy protein isolate for 2 years did not reduce or delay development of biochemical recurrence of prostate cancer compared to men who received placebo, according to a study in the July 10...

prostate cancer

Active Surveillance May Miss Aggressive Prostate Cancers in African American Men

A study of more than 1,800 men aged 52 to 62 suggests that African Americans diagnosed with very low-risk prostate cancers are much more likely than white men to actually have aggressive disease that goes unrecognized with current diagnostic approaches. Although prior studies have found it safe to...

prostate cancer

Use of Advanced Treatment Technologies Increases among Men at Low Risk of Dying from Prostate Cancer

Use of advanced treatment technologies for prostate cancer, such as intensity-modulated radiotherapy (IMRT) and robotic prostatectomy, has increased among men with low-risk disease, high risk of noncancer mortality, or both, a population of patients who are unlikely to benefit from these...

prostate cancer

Observation Is Safe, Cost-saving Option for Patients with Low-risk Prostate Cancer

Many men with low-risk, localized prostate cancers can safely choose active surveillance or watchful waiting instead of undergoing immediate treatment and have better quality of life while reducing health-care costs, according to a study by researchers at Dana-Farber Cancer Institute and...

prostate cancer

New Possibilities for Prostate Cancer Treatment

An Australian study has identified a subgroup of prostate cancer cells that survive androgen deprivation therapy and could contribute to prostate cancer recurrence. Previously unidentified, these cells are potential targets for future treatments. As they are present early in disease development,...

prostate cancer

Researchers Identify Novel Class of Drugs for Prostate Cancers

A new study on prostate cancer describes a novel class of drugs developed by UT Southwestern Medical Center researchers that interrupts critical signaling needed for prostate cancer cells to grow. In men with advanced prostate cancer, growth of cancer cells depends on androgen receptor signaling,...

prostate cancer

Mayo Clinic Genomic Analysis Lends Insight to Prostate Cancer

Mayo Clinic researchers have used next-generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings appear online today in the journal Cancer Research. Gleason Patterns...

Advertisement

Advertisement



;
Advertisement